Funding

Grants Awarded for Gene Therapy Approaches to Treat HIV and Cancer

Published in AIDS Weekly, September 15th, 1997

Avigen, Inc., Alameda, California, announced the receipt of a grant from the U.S. National Institutes of Health (NIH) and one from the University of California (UC) aimed at advancing research on gene therapy approaches to treat HIV infections and cancer.

The NIH Grant is a renewal of a National Cooperative Drug Discovery Grant (NCDDG) supporting the development of a "Trojan horse" approach to treating HIV infections called "Capsid Targeted Viral Inactivation" (CTVI). In this approach, Avigen and its collaborators deliver to HIV-infected cells a gene coding for a modified version of one of the HIV proteins.

When the virus replicates in a cell...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of AIDS Weekly

Source: AIDS Weekly (1997-09-15)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry